Guggenheim Reiterates Buy on Johnson & Johnson, Maintains $287 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 81.7%

Neg 0% Neu 81.7% Pos 0%

Guggenheim analyst Vamil Divan reiterates Johnson & Johnson (NYSE:JNJ) with a Buy and maintains $287 price target.

Comments

No comments yet. Be the first!